Sphenopalatine Ganglion Pulsed Radiofrequency Treatment Outcomes
CompletedNot applicableNCT07370142
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Purpose of the Study: This study aims to evaluate the clinical effectiveness and long-term outcomes of "Sphenopalatine Ganglion (SPG) Pulsed Radiofrequency (PRF)" treatment in patients with chronic headaches and facial pain. The SPG is a major neural junction for craniofacial pain signaling. PRF is a safe, minimally invasive technique that modulates pain transmission without causing thermal damage to the nerve tissue. Methodology: The study will include 55 volunteer patients at the Ankara Bilkent City Hospital Algology Clinic who are unresponsive to medical treatments. Patients will undergo the standard "fluoroscopy-guided infrazygomatic approach." Pain intensity (VAS), quality of life, patient satisfaction, and changes in analgesic consumption will be recorded at baseline and during follow-up visits at 1 week, 1 month, 3 months, and 6 months post-procedure using various clinical parameters. Expected Benefits and Risks: The research intends to provide evidence regarding the 6-month long-term impact of this intervention on pain scores and patient well-being. Since the study follows routine clinical practices, it poses no additional risks to participants and aims to optimize future treatment strategies.
Study details
- Official title
- Clinical Outcomes of Sphenopalatine Ganglion Pulsed Radiofrequency in Refractory Craniofacial Pain Syndromes: A Prospective Clinical Study
- Conditions
- Migraine Disorders, Facial Pain Disorder, Cluster Headache, Trigeminal Neuralgia, Trigeminal Autonomic Cephalalgias
- Interventions
- Procedure: Pulsed Radiofrequency of the Sphenopalatine Ganglion
- Sponsor
- Ankara City Hospital Bilkent
- Start date
- 2025-03-20
- Primary completion
- 2025-10-01
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Turkey (Türkiye)
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients aged 18 years and older (no upper age limit) * Patients diagnosed with refractory chronic headache (including cluster headache, migraine, paroxysmal hemicrania, hemicrania continua, SUNCT, or SUNA) or chronic orofacial pain / trigeminal neuralgia * Pain duration of at least 3 months * Pain intensity score (VAS or NRS) \> 3 out of 10 * Patients unresponsive to conservative medical treatments * Patients scheduled for sphenopalatine ganglion (SPG) pulsed radiofrequency (PRF) treatment as part of routine clinical care * Ability and willingness to provide written informed consent Exclusion Criteria: * Systemic infection or local skin infection at the needle insertion site * Known coagulopathy or bleeding disorders * Presence of a cardiac pacemaker or implantable cardioverter-defibrillator (ICD) * Presence of an intracranial mass or significant anatomical distortion in the pterygopalatine fossa region * Previous surgical intervention involving the sphenopalatine ganglion * Pregnancy or breastfeeding * Severe psychiatric or cognitive disorders preventing reliable pain assessment or follow-up * Hemodynamic instability * Refusal to participate in the study or undergo the procedure
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07370142